VRM
AVXL icon

Vectors Research Management’s Anavex Life Sciences AVXL Stock Holding History

Vectors Research Management’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,000
Closed -$20K – 164
2022
Q2 		$20K Buy
+2,000
New +$18.9K 0.01% 282
2022
Q1 		– Sell
-1,000
Closed -$17K – 475
2021
Q4 		$17K Hold
1,000
– – ﹤0.01% 351
2021
Q3 		$18K Hold
1,000
– – ﹤0.01% 313
2021
Q2 		$23K Buy
+1,000
New +$14.8K 0.01% 304

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
PC
Pier Capital Stamford, Connecticut $755M AUM 94.38% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Vectors Research Management's AVXL Position: Q3 2022 in Review

Vectors Research Management sold out of Anavex Life Sciences (AVXL) in Q3 2022, closing a stake of 2,000 shares — an estimated $20K sold.

Vectors Research Management first reported a position in AVXL in Q2 2021 and held it in 4 quarters. The position peaked at $23K in Q2 2021. 147 funds tracked by Wall St. Rank hold AVXL as of Q3 2022.

  • Vectors Research Management reported no remaining Anavex Life Sciences position as of Q3 2022 after selling out during the quarter.
  • Vectors Research Management sold 2,000 Anavex Life Sciences shares in Q3 2022, an estimated $20K.
  • Vectors Research Management first reported a position in Anavex Life Sciences in Q2 2021 and held it in 4 quarters.
  • Vectors Research Management's Anavex Life Sciences position peaked at $23K in Q2 2021.
  • 147 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q3 2022.

Based on Vectors Research Management's 13F filing for Q3 2022, filed 8 Nov 2022.